56 results

... assessed harms at 12 weeks, while the oral DHEA trial 129 had a 52-week followup period. One trial 128 evaluated safety only to state that there were no drug- ...

... Adams J., Morrow C., Davis S. R. The safety of 52 weeks of oral DHEA therapy for postmenopausal women. Maturitas. 2009; 63 (3): ...

... M, Bell RJ, Jane F, et al. The safety of 52 weeks of oral DHEA therapy for postmenopausal women. Maturitas. 2009 Jul 20; ...

... estrogen receptor agonist activity in vaginal tissue. For DHEA and testosterone, we included both vaginal and systemic formulations, but evaluated efficacy and safety separately for vaginal and systemic formulations. For studies ...

... A. A comparative study of CEE, tibolone, and DHEA as hormone replacement therapy for surgical ... and safety of prolonged-release hyaluronic acid derivative vaginal application ...

... menopause ( GSM ). We found that vaginal estrogen, vaginal dehydroepiandrosterone ( DHEA ), oral ospemifene, and vaginal moisturizers may all improve ... with vaginal bleeding, discharge, and breast tenderness; vaginal DHEA was associated with increased facial hair, voice changes, ...

... wort, ginseng, flax seed, vitamin E, dong quai, DHEA, other herbal ingredients, and combinations of nonprescription agents. ... 128 St. John’s wort, 126 , 128 , 129 DHEA, 130 and other nutritional supplements. 131 - 133 Eleven ...

... Medroxyprogesterone or Progesterone or androgen* or testosterone or Dehydroepiandrosterone or Norethindrone):ti,ab,kw #30 (cholinesterase or ... 86 Progesterone Congeners/ 87 Androgens/ 88 Testosterone/ 89 Dehydroepiandrosterone/ 90 Dehydroepiandrosterone Sulfate/ 91 Norethindrone/ 92 Hormone Replacement ...

... Two major androgens in women are testosterone and dehydroepiandrosterone (DHEA). In women with naturally occurring menopause, there is ... effect on menopausal women experiencing sexual dysfunction. 18 DHEA is available without prescription as a dietary supplement, ...